MultiCell Develops Improved Cell Culture Media Supplement, MFE Supplement A; Four Immortalized Hepatocyte Posters presented at ISSX.

LINCOLN, R.I. -- MultiCell Technologies, Inc. (OTCBB: MCET) announced today that XenoTech LLC, MultiCell's marketing and manufacturing licensee, introduced an improved cell culture media supplement called MFE Supplement A on October 25th at the joint ISSX / JSSX Meeting in Hawaii and presented latest data on the cell line and media with a scientific poster presentation.

MultiCell's new exclusive culture media supplement enhances the sensitivity of the cells to detect CYP3A4 inducers, which improves the ability of the cells to detect those drug candidates that have a high potential to cause certain types of drug-drug interactions.

MultiCell's progenitor cells and immortalized liver cells are used by XenoTech, Pfizer, Bristol Myers Squibb and a growing number of other pharmaceutical companies to improve the safety profile of drugs by identifying early in the drug development program those drug candidates that can cause clinically significant enzyme induction and drug-drug interactions. The cells are available in a variety of formats (cryopreserved or ready to use plates) for testing drug candidates to help lower drug development costs and help prevent costly drug recalls. In June, MultiCell announced sales of its immortalized human hepatocytes (Fa2N-4 cells) in shrink-wrapped vials and plates, allowing purchase of cells without no-grow agreements. By opening the wrap, a user indicates acceptance of the no-grow terms of a one-time use license. The companies now recommend, for best results, ordering a complete package of hepatocytes, culture media, and supplement A. Call XenoTech at 1 (913) GET- P450 and ask for the current special package promotional offer.

MultiCell's immortalized human hepatocytes are pharma-tested cell lines proven useful for identifying drugs that increase CYP1A2 and CYP3A4 drug metabolizing enzymes. Drugs that increase the expression of these two major drug metabolizing enzymes may lead to adverse drug reactions including drug-drug interactions. The use of the Company's immortalized cell lines permits standardization of CYP induction assays, facilitates comparison of historical data , and eliminates the problem of limited supply and organ donor variability that restrict the use of primary human liver cells for enzyme induction studies. MultiCell's cell lines, now with improved culture media, may save years of time as well as millions of dollars during pre-clinical drug discovery, development and testing stages.

Four posters were presented at ISSX showing good results from MultiCell's hepatocytes:

--"Comparative Evaluation of CYP3A4 Induction Assay Using PXR Report Gene Constructs, Immortalized and Primary Human Hepatocytes" was presented by Yang Sai of Neurocrine Biosciences.

--"Cytochrome P450 Induction in the Fa2N-4 Immortalized Human Hepatocyte Cell Line and Primary Cultures of Human Hepatocytes" by Dan Brobst of University of Kansas.

--Kevin Lyon of XenoTech presented Scientific Poster number 255, "Improving the dynamic range of CYP3A4 induction in immortalized human hepatocytes (Fa2N-4 cells)"

--"Clinical Prediction of CYP3A4 Induction Using Immortalized Human Hepatocytes" was presented by Matthew Troutman of Pfizer.

About MultiCell Technologies, Inc.

MultiCell Technologies is a developer of therapeutics, an adult stem cell company and a supplier of immortalized cell lines for drug discovery applications. With its subsidiary, MultiCell Immunotherapeutics, Inc. (MCTI), MultiCell intends to commercialize new therapeutics for the treatment of various diseases and disorders. MultiCell holds key patents relating to novel strategies for the isolation of adult human liver cells, and cell clusters or doublets as well as additional patents in the areas of stem cell technology, the Sybiol(R) synthetic bio-liver therapeutic liver assist device, and immortalized human hepatocytes. MultiCell's stem cells are derived from adult tissue, avoiding the ethical and contamination issues associated with embryonic stem cells. MultiCell's headquarters and research laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties we face, see documents we file with the SEC, including our Report on Form 10-KSB for the fiscal year ended November 30, 2004 and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.